Astellas has won a reprieve in its attempt to stop Pfizer's generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a ...
According to IQVIA figures, US sales of Lexiscan were approximately $650 million for the 12 months that ended 31st March 2022, making it one of Astellas' top products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback